Brief: Innate Pharma: 1st Patient Dosed In Phase 2 Matisse Trial Of IPH5201 In Early Stage Lung Cancer

Innate Pharma SA

26/06/2023 06:05

June 26 (Reuters) - Innate Pharma SA  IPH.PA :
    * FIRST PATIENT DOSED IN PHASE 2 MATISSE TRIAL OF IPH5201 IN
EARLY
STAGE LUNG CANCER
    * PHASE 2 MATISSE TRIAL IS EVALUATING IPH5201, AN ANTI-CD39
BLOCKING MONOCLONAL ANTIBODY, IN COMBINATION WITH IMFINZI
(DURVALUMAB) AND CHEMOTHERAPY IN EARLY STAGE LUNG CANCER
    * PRIMARY OBJECTIVES OF STUDY ARE TO ASSESS ANTITUMOR
ACTIVITY OF
NEOADJUVANT TREATMENT BASED ON PATHOLOGICAL COMPLETE RESPONSE
(PCR) AND SAFETY
    * IPH5201 IS DEVELOPED IN COLLABORATION WITH ASTRAZENECA
 AZN.L 
    * INNATE IS RESPONSIBLE FOR CONDUCTING STUDY AND SHARES
STUDY
COSTS WITH ASTRAZENECA (LSE/STO/NASDAQ: AZN). ASTRAZENECA
SUPPLIES CLINICAL TRIAL DRUGS
    * INNATE RECEIVED A $5M MILESTONE PAYMENT FROM ASTRAZENECA
WHEN
DECISION WAS MADE TO PROGRESS IPH5201 TO A PHASE 2 CLINICAL
TRIAL.

Source text for Eikon:  ID:nBw9QB6dGa 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))